Skip to main content
Download PDF

The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis

BMC Infectious Diseases volume 23, Article number: 543 (2023) Cite this article

Abstract

Background

Helicobacter pylori is a gastrointestinal pathogen that infects around half of the world's population. H. pylori infection is the most severe known risk factor for gastric cancer (GC), which is the second highest cause of cancer-related deaths globally. We conducted a systematic review and meta-analysis to assess the global prevalence of GC in H. pylori-infected individuals.

Methods

We performed a systematic search of the PubMed, Web of Science, and Embase databases for studies of the prevalence of GC in H. pylori-infected individuals published from 1 January 2011 to 20 April 2021. Metaprop package were used to calculate the pooled prevalence with 95% confidence interval. Random-effects model was applied to estimate the pooled prevalence. We also quantified it with the I2 index. Based on the Higgins classification approach, I2 values above 0.7 were determined as high heterogeneity.

Results

Among 17,438 reports screened, we assessed 1053 full-text articles for eligibility; 149 were included in the final analysis, comprising data from 32 countries. The highest and lowest prevalence was observed in America (pooled prevalence: 18.06%; 95% CI: 16.48 − 19.63; I2: 98.84%) and Africa (pooled prevalence: 9.52%; 95% CI: 5.92 − 13.12; I2: 88.39%). Among individual countries, Japan had the highest pooled prevalence of GC in H. pylori positive patients (Prevalence: 90.90%:95% CI: 83.61–95.14), whereas Sweden had the lowest prevalence (Prevalence: 0.07%; 95% CI: 0.06–0.09). The highest and lowest prevalence was observed in prospective case series (pooled prevalence: 23.13%; 95% CI: 20.41 − 25.85; I2: 97.70%) and retrospective cohort (pooled prevalence: 1.17%; 95% CI: 0.55 − 1.78; I 2: 0.10%).

Conclusions

H. pylori infection in GC patients varied between regions in this systematic review and meta-analysis. We observed that large amounts of GCs in developed countries are associated with H. pylori. Using these data, regional initiatives can be taken to prevent and eradicate H. pylori worldwide, thus reducing its complications.

Peer Review reports

Background

Helicobacter pylori (H. pylori) is a bacterial pathogen associated with the gastrointestinal (GI) tract of over 50% of the world’s population [1]. H. pylori, is a Gram-negative spiral-shaped bacterium that colonizes the stomach, was graded as a Group I carcinogen in 1994 by the International Agency for Research on Cancer [2]. With its flagella, H. pylori is capable of moving and can survive on stomach acids, leading to colonization of GI tract cells and irritation and inflammation [3]. Epidemiologic and clinical data have demonstrated the role of H. pylori in up to 75% of non-cardia gastric malignancies and up to 98% of gastric cardia malignancies [4]. There is a strong correlation between gastric cancer (GC) and H. pylori infection [5].

Gastric cancer (GC) is the fifth most common cancer in the world and has the third highest mortality rates, for both sexes [6]. In 2020, actually 1.09 million new GC cases and 0.77 million deaths from GC was estimated all over the world [7]. The overall yearly incidence rates globally are 15.6 to 18.1 and 6.7 to 7.8 per 100,000 individuals in men and women, respectively [8]. According to anatomical subsites, GC can be classified into two categories: cardia GC and non-cardia GC [9]. Cardia and non-cardia GC are treated as two different diseases due to different epidemiological characteristics and distinct pathogeneses. Non-cardia GC is more common than cardia GC. Non-cardia GC accounted for up to 82% of all GC cases around the world in 2018 [10].

The high incidence of H. pylori infection is not always associated with high prevalence of GC. This enigma of H. pylori infection and GC, defined by a very high incidence of infection but a low rate of GC, was first described by Holcombe in 1992 as the "African Enigma" [11]. Hence, the African enigma represents a modification of the inflammatory response triggered by the infection, leading to the absence of any neoplastic manifestations [11]. Other countries including China, Colombia, India, Costa Rica, and Malaysia have described similar enigmas [11]. Several previous studies have suggested that an increased risk of GC is associated with lifestyle behaviors, such as cigarette smoking, intensive alcohol consumption, high salt intake, consumption of processed meat, and low intake of fruits [12]. In addition, host’s genetics has been associated with GC. Mutation in CDH1 gene that encodes E-cadherin protein for cell–cell adhesion has been associated with more than 80% increased risk of GC, and patients with reduced expression of the E-cadherin protein have a poor prognosis [13].

The majority of infections are asymptomatic, therefore a screening and treatment program cannot be justified except for high-risk patients [14]. However, the inflammatory response to an infection in a host and the virulence of the infection vary between individuals. Additionally, environmental exposures may also contribute to the increase in the risk of GCs [15]. Infection prevalence shows large geographical variations. In general, the prevalence of infection is higher in developing countries than developed countries such as Europe and North America [16]. Despite the global prevalence of GC in people with H. pylori infection was reported by Pormohammad et al. [1], a complete up-to-date research on the prevalence of GC in people with H. pylori infection has not been done yet. In the previous study, only studies conducted until 2016 were evaluated. However, in this review, statistics until 2021 were considered. Also, there were several differences between 2 studies in terms of the data bases, time period of search, eligibility criteria, and keywords. Hence, this study aimed to update the GC estimate in H. pylori positive patients after reviewing existing evidence and reassessing the global burden of GC caused by H. pylori in different regions.

Methods

Search strategy

PubMed, Web of Science, and Embase were searched from1 January 2011 to 20 April 2021 to retrieve all relevant studies in the world. MeSH keywords and search strategy were as below: 'Stomach Neoplasm' [tiab], OR 'Cancer of Stomach' [tiab], OR 'Gastric Cancer' [tiab], OR 'Cancer of Gastric' [tiab], OR '' Stomach Cancer '[tiab], OR 'Neoplasm of Stomach' [tiab] AND 'Helicobacter pylori' [tiab], OR 'Campylobacter pylori' [tiab], OR 'Campylobacter pylori subsp. pylori' [tiab] OR, 'Campylobacter pyloridis' [tiab], OR 'Helicobacter nemestrinae' [tiab] AND 'Prevalence' [tiab], OR 'Frequency' [tiab].

Eligibility criteria

We set our inclusion and exclusion criteria based on PECOTS criteria (population, exposure, comparison, outcome, time and study design) (Table 1). For that, all cross-sectional, prospective and retrospective case-series studies which reported the prevalence of GC in H. pylori patients were included. However, case reports and case series with less than five patients (as study population) and also clinical trial studies were excluded. Also, studies without reported prevalence data, definite sample sizes, and clear correct estimates of the prevalence, as well as case–control studies and abstracts presented in scientific meetings with no sufficient data were excluded from this study.

Table 1 PECOTS criteria of the study
Full size table

Study selection

There were 17,438 results from the initial search. Two authors (SK and RP) separately assessed these papers' eligibility, and any discrepancies were settled by consensus. The following step involved excluding 5380 duplicate articles. Also, after reviewing the titles and abstracts of the remaining publications, 11,058 papers were omitted. Of the remaining 1053 articles, 904 ineligible articles were omitted during the review of the entire texts. Eventually, 149 articles that qualified for inclusion were examined.

Quality assessment

Newcastle Ottawa scale (NOS) was used to measure the quality of studies (Table 2). This scale is used to measure the quality of observational studies including cohort, cross-sectional and case series studies. The validity and reliability of this tool have been proven in various studies [17, 18].

Table 2 Quality assessment of studies by Newcastle Ottawa Scale (NOS) checklist
Full size table

Data extraction

Two authors independently performed the study selection and validity assessment and resolved any disagreements by consulting a third researcher. First author, country, enrollment time, published time, type of study, number of Hp+ patients, mean age in Hp+ patients, detection method of Hp, number of patients with cancer, sort (name) of cancer, diagnosis method of GC, and prevalence (95% CI) were extracted from articles.

Statistical analysis

All statistical tests in this study were performed with Stata 14.0. As previous researches [91, 92] the sample size, the number of patients with H. pylori, number of cancer cases in patient with H. pylori, and prevalence of GC in H. pylori positive patients were extracted. We applied Cochran's Q test to determine the heterogeneity. We also quantified it with the I2 index. Based on the Higgins classification approach, I2 values above 0.7 were determined as high heterogeneity. We used random effects model to estimate pooled values where that heterogeneity was high. Also we used the subgroup analysis and meta-regression analysis to find out the heterogeneity sources. Metaprop package were used to calculate the pooled prevalence with 95% confidence interval. Random-effects model was applied to estimate the pooled prevalence. This package applies double arcsine transformations to stabilize the variance in the meta-analyses. The effects of publication time, continents, age mean, sample size and study design on the studies heterogeneity were analyzed by univariate and multiple meta-regression analysis. Publication bias evaluated by “metabias” command. In case of any publication bias, we adjusted the prevalence rate with “metatrim” command applying trim-and-fill approach. Statistical significance was considered 0.05.

Result

A total of 149 studies with 352,872 total sample size were included in our study. Selection process flow chart is available in Fig. 1, and Table 3 shows the studies’ characteristics such as first author, country, published time and type of study. Several primary studies reported overall number of gastric cancer and do not present more detail about cancer. But some primary studies presented more detail about cancer such as anatomical location of it. Many studies mentioned they used histopathology method to detection of cancer. The highest studies number belonged to Asia continent (114 studies) area and Africa continent (6 studies) was the lowest one. All the included studies were published during 1 January 2011 to 20 April 2021. The minimum and maximum age range of the subjects was for Haddadi et al. [93] article with the age ranges (mean age = 26 years old) and Shibukawa et al. [94] study with the mean age = 73 years old, respectively. Sixty-nine (46.31%) of studies were cross sectional, sixty-four (42.95%) of studies were case series and sixteen (10.73%) of studies were cohort.

Fig. 1
figure 1

Flow diagram of study selection

Full size image
Table 3 Characteristics of studies included in the meta-analysis
Full size table

Pooled prevalence of GC in H. pylori positive patients

Figure 2 shows the forest plot of prevalence of GC in H. pylori positive patients. Minimum and maximum prevalence were in Doorakkers et al. [107] study (Prevalence: 0.07%; 95% CI: 0.06–0.09) from the Sweden and Tanaka et al. [161] (Prevalence: 90.90%:95% CI: 83.61–95.14) from Japan, respectively. Due to high heterogeneity and different study design, results don’t merge and presented based on different subgroups

Fig. 2
figure 2

Forest plot of prevalence of gastric cancer in Helicobacter pylori positive patients

Full size image

Pooled prevalence of gastric cancer in H. pylori positive patients based on different subgroups

Pooled prevalence of GC in H. pylori positive patients based on study design and continents are listed in Fig. 3 and Table 4. Based on design, the highest and lowest prevalence was observed in prospective case series (pooled prevalence: 23.13%; 95% CI: 20.41 − 25.85; I2: 97.70%) and retrospective cohort (pooled prevalence: 1.17%; 95% CI: 0.55 − 1.78; I 2: 0.10%), respectively. Also based on continents, the highest and lowest prevalence was observed in America (pooled prevalence: 18.06%; 95% CI: 16.48 − 19.63; I2: 98.84%) and Africa (pooled prevalence: 9.52%; 95% CI: 5.92 − 13.12; I2: 88.39%) continents, respectively.

Fig. 3
figure 3

Pooled prevalence with 95% confidence interval [CI] and heterogeneity indexes of gastric cancer in Helicobacter pylori positive patients based on type of the design and continents places. The diamond mark illustrates the pooled prevalence and the length of the diamond indicates the 95% CI

Full size image
Table 4 Result of meta-analysis, publication bias and fill-trim method for prevalence estimate and corresponding 95% confidence interval of gastric cancer in H.pylori positive patients
Full size table

Heterogeneity and meta‐regression

Heterogeneity results are available in Table 4. Cochran's Q test showed the included studies had high heterogeneity (p < 0.001). The I2 index for total prevalence was up to 98%. The result of univariate meta‐regression analysis (Table 5) showed the age (Coefficient: 0.59; p: 0.009), sample size (Coefficient: − 0.1; p: 0.003) and study design (based WHO regional office) (Coefficient: 3.72; p: 0.015) possess significant effect on the studies heterogeneity (Fig. 4A and B) and have eligible to include to multiple model. The result of multiple meta‐regression analysis showed the just age (Coefficient: 0.66; p: 0.003) have a significant effect on the studies heterogeneity. The R2-adj for multiple model was 13.63% and this mean the age, Sample size and study design explained the about 14% of total heterogeneity of prevalence.

Table 5 The univariate and multiple meta-regression analysis on the determinant heterogeneity in effect of iron therapy on depression
Full size table
Fig. 4
figure 4

Association between Pooled prevalence of gastric cancer in Helicobacter pylori positive patients with age (A) and publication year (B) by means of meta-regression. The size of circles indicates the precision of each study. There is a positive significant association with respect to the pooled prevalence with age

Full size image

Publication bias

The results of Egger’s test showed significant publication bias in our meta-analysis which provided in Table 4. For adjustment of pooled prevalence, fill and trim method was used that result was showed in Table 4. Based on this result, publication-bias-adjusted pooled prevalence estimation for cross sectional was 7.89% (95% CI: 6.78—9.01) which was different with pooled prevalence estimation based on meta-analysis 19.46% (95% CI: 18.34 to 20.57). Result of fill and trim method for other subgroups was showed in Table 4.

Discussion

Infection with H. pylori causes chronic inflammation and significantly increases the risk of developing duodenal and gastric ulcer disease and GC. H. pylori primarily infect the epithelial cells in the stomach and can survive in humans for decades by inhibiting the immune system responsiveness, results inducing chronic inflammatory responses. Because of endotoxin elaboration and other inflammatory exudates, the colonization of the gastric mucosa by H. pylori has been observed with gastric atrophy [173]. Researchers have recently reported molecular aspects that highlight the importance of certain apoptotic genes and proteins including C-Myc, P53, Bcl2, and Rb-suppressor systems in H. pylori pathogenesis. H. pylori infection has also been shown to be related to nitric oxide (NOSi genotype) [70]. Induction of apoptosis in gastric mucosa by H. pylori involves upregulation of Bax and Bcl-2 [70].

With H. pylori involvement in the gastric intestinal pH alteration, dysplasia has been observed in patients with H. pylori infection [174]. Previous studies have been shown that individuals who had been infected with H. pylori were six times more likely to develop GC compared with healthy people [175]. In this study, using random-effects model approach, pooled prevalence of GC in H. pylori positive patients was 8.97% (95% CI: 8.62–9.33) [N = 149; I2 = 98.68%]. Therefore, from every 1000 H. pylori positive patients, 8.62 to 9.33 individuals get GC. The frequency of H. pylori in people less than 50 years old was reported as 41.9%.

The study by Vohlonen et al. showed risk ratio (RR) of stomach cancer in people with H. pylori infection was 5.8 (95%CI: 2.7–15.3) compared to people with healthy stomachs, and 9.1 (95%, CI: 2.9–30.0) in men with atrophic gastritis [86]. The present observation also demonstrated that an H. pylori infection alone (non-atrophic H. pylori gastritis) is by itself a clear risk condition for GC as was suggested by the IARC/WHO statement in 1994 [176]. In study conducted before 1998, by approximately 800 GC cases, the analysis yielded a risk ratios of 2.5 (95% CI: 1.9–3.4) for GC in H. pylori-seropositive people [177]. Another study including 233 GCs and 910 controls, yielded a risk ratios of 6.5 (95%CI: 3.3–12.6) for non-cardia GC in subjects infected with a cytotoxic (CagA) H. pylori strain [178]. In another study, the risk ratios of GC was 3.1 (95%CI: 1.97–4.95) between H. pylori infected and non-infected persons [179]. The risk ratios, based on case–control study designs, varied between 1.6 and 7.9 in three published papers from two extensive prospective nutritional intervention trials of over 29,000 males at age of 50–69 years in Linxian, China and Finland [180,181,182].

Our estimate of the prevalence of GC due to H. pylori infection in cross sectional studies was 19.46% (95% CI: 18.34—20.57) [N = 69; I2 = 98.59%], Therefore, from every 1000 H. pylori positive patients, 183 to 206 individuals get GC.

The simple infection markedly increases the cancer risk when compared to a healthy stomach. The risk varies between the populations with the highest and lowest by 15 to 20 times. East Asia (China and Japan), South America, Eastern Europe, and Central America are the high-risk regions. North and East Africa, North America, Southern Asia, New Zealand, and Australia are the low-risk regions [183].

Our study noted the lowest prevalence of GC in H. pylori positive patients from the Sweden (Prevalence: 0.07%; 95% CI: 0.06–0.09) [107] and the highest from the Japan (Prevalence: 90.90%:95% CI: 83.61–95.14) [161].

This difference may be due to the following reasons: dietary habits, socio-economic status and racial disparities. Suerbaum et al. [184] have mentioned that populations with lower socioeconomic status were more likely to be infected with H. pylori. Data based on National Health and Nutrition Examination Surveys of the United States have also shown that racial disparities played a certain role in the prevalence of H. pylori. The prevalence of H. pylori in African Americans was higher than whites [185]. The findings of the studies showed that Blacks and Hispanics consistently have higher H. pylori prevalence, serologic markers, and histologic signs than whites. Generally, the prevalence of CagA in adult people with H. pylori positivity ranged from 71%-90% in blacks, 64%-74% in Hispanics, and 36% to 77% in whites. Studies that amplified the VacA m allelic region for genomic characterization discovered that Blacks and Hispanics were more likely than whites to carry the virulent VacA-m1 genotype [186]. It has been hypothesized that racial discrepancies associated with H. pylori are contributed to GC incidence and mortality.

The evidence that is currently available implies that practitioners should be aware that the prevalence of H. pylori varies depending on race [187]. Perhaps it would be better if we personalized GC prevention and improved clinical management for all patients.

The results of subgroup analysis, based on our design, the highest and lowest prevalence was observed in prospective case series (pooled prevalence: 23.13%; 95% CI: 20.41 − 25.85; I2: 97.70%) and retrospective cohort (pooled prevalence: 1.17%; 95% CI: 0.55 − 1.78; I 2: 0.10%). The highest and lowest prevalence of GC in H. pylori patients was observed in America (pooled prevalence: 18.06%; 95% CI: 16.48 − 19.63; I2: 98.84%) and Africa (pooled prevalence: 9.52%; 95% CI: 5.92 − 13.12; I2: 88.39%) continents, respectively.

Steady declines in GC incidence rates have been observed worldwide in the last few decades [183]. The general declining incidence of GC may be explained by higher standards of hygiene, improved food conservation, a high intake of fresh fruits and vegetables, and by H. pylori eradication [188]. Current treatment for H. pylori infection includes antisecretory agents or bismuth citrate plus two or more antimicrobials. Clarithromycin and metronidazole are the most commonly used antibiotics to treat H. pylori infection. Increasing resistance of H. pylori to metronidazole and clarithromycin has made current therapies with these antibiotics less successful [68]. Bismuth triple therapy is not very effective in the presence of a high prevalence of metronidazole resistance, unless higher doses of metronidazole are prescribed to increase the cure rate of therapy. Resistance to the major anti-H pylori antibiotics, the final duration of therapy, and the prescribed antibiotic dose are all factors that affect the efficacy of therapy. Host genetic polymorphisms may also influence the efficacy of therapy [189].

The results of our study indicated a significant heterogeneity (p < 0.001) in the prevalence of H. pylori in GC across different geographical regions. The result of univariate meta‐regression analysis showed the age, sample size and study design possess significant effect on the studies heterogeneity and have eligible to include to multiple model. The results of multiple meta‐regression analysis showed the just age have a significant effect on the studies heterogeneity. The R2-adj for multiple model was 13.63% and this mean the age, sample size and study design explained the about 14% of total heterogeneity of prevalence. This was in accordance with a recent study that assessed the prevalence of H. pylori in gastrointestinal disease cases [97]. Study performed by Spineli et al. [98] revealed that subgroup analysis may not be powerful enough to test for relationships between variables when fewer studies are involved. However, type of sample was significantly associated with H. pylori prevalence [184]. Although subgroup analysis and meta-regression were performed to minimize the heterogeneity across the included studies, significant heterogeneity still could be observed in subgroup analysis. Moreover, some important factors like drinking and dietary habit could not be extracted from the included studies, which might have potential influence on the heterogeneity.

Therefore, these results should be considered with caution and more studies are needed to further confirm these results in the future.

In general, limitations of meta-analyses are that the validity is dependent on the quality of the included studies, on heterogeneity between studies, and on possible publication bias; but we tried to deal of them by statistical manner. Indeed we dealt to heterogeneity by using random effects model, subgroup and meta-regression analysis. Also we tried to deal publication bias by use the fill and trim method to estimate the publication-bias-adjusted-pooled.

Conclusions

In our study by evaluate the 149 studies and 352,872 sample size illustrated that prevalence of GC in patient with H. pylori was considerable. But the rate was varied based on different subgroups so that the rate was highest among in America continent but was lowest in Africa continent. Also, using meta-regression and assessment the effect of several variables, indicated that age, sample size and study design explained the about 14% of total heterogeneity. It is advised to launch appropriate control guidelines for high-risk region. The risk of different factors should also be taken into account when developing GC decrease strategies, even though H. pylori eradication may be a promising method for preventing the disease.

Availability of data and materials

All data generated or analyzed during this study are included here and are available from the corresponding author on reasonable request.

Abbreviations

GC:

Gastric cancer

NOS:

Newcastle Ottawa scale

PRISMA:

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RR:

Risk ratio

References

  1. Pormohammad A, Mohtavinejad N, Gholizadeh P, Dabiri H, Salimi Chirani A, Hashemi A, et al. Global estimate of gastric cancer in Helicobacter pylori–infected population: a systematic review and meta-analysis. J Cell Physiol. 2019;234(2):1208–18.

    CAS  PubMed  Google Scholar 

  2. Jia Z, Zheng M, Jiang J, Cao D, Wu Y, Zhang Y, et al. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. BMC Cancer. 2022;22(1):1–15.

    Google Scholar 

  3. Haley KP, Gaddy JA. Helicobacter pylori: genomic insight into the host-pathogen interaction. Int J Genomics. 2015;2015:386905.

    PubMed  PubMed Central  Google Scholar 

  4. Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Díaz P, Valenzuela Valderrama M, Bravo J, Quest AF. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol. 2018;9:5.

    PubMed  PubMed Central  Google Scholar 

  6. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.

    CAS  PubMed  Google Scholar 

  7. Lu Y, Xiao F, Wang Y, Wang Z, Liu D, Hong F. Prevalence of helicobacter pylori in non-cardia gastric cancer in China: a systematic review and meta-analysis. Front Oncol. 2022;12:850389.

    PubMed  PubMed Central  Google Scholar 

  8. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    PubMed  Google Scholar 

  9. Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564–71.

    PubMed  Google Scholar 

  10. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90.

    PubMed  Google Scholar 

  11. Ghoshal UC, Chaturvedi R, Correa P. The enigma of Helicobacter pylori infection and gastric cancer. Indian J Gastroenterol. 2010;29:95–100.

    PubMed  PubMed Central  Google Scholar 

  12. International WCRF. Diet, nutrition, physical activity and cancer: a global perspective: a summary of the Third Expert Report: World Cancer Research Fund International. 2018.

    Google Scholar 

  13. Liu X, Chu KM. E-cadherin and gastric cancer: cause, consequence, and applications. BioMed Res Int. 2014;2014.

  14. Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench. 2015;8(Suppl1):S6.

    PubMed  PubMed Central  Google Scholar 

  15. Balakrishnan M, George R, Sharma A, Graham DY. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep. 2017;19(8):1–10.

    Google Scholar 

  16. Pounder R, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995;9:33–9.

    PubMed  Google Scholar 

  17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article  PubMed  Google Scholar 

  18. Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B, et al. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. The Lancet. 2016;388(10041):258–67.

    Google Scholar 

  19. Dadashzadeh K, Peppelenbosch MP, Adamu AI. Helicobacter pylori pathogenicity factors related to gastric cancer. Can J Gastroenterol Hepatol. 2017;2017:7942489.

    PubMed  PubMed Central  Google Scholar 

  20. Yakoob J, Abbas Z, Jafri W, Khan R, Salim SA, Awan S, et al. Helicobacter pylori outer membrane protein and virulence marker differences in expatriate patients. Epidemiol Infect. 2016;144(10):2200–8.

    CAS  PubMed  Google Scholar 

  21. Yang TT, Cao N, Zhang HH, Wei JB, Song XX, Yi DM, et al. Helicobacter pylori infection-induced H3Ser10 phosphorylation in stepwise gastric carcinogenesis and its clinical implications. Helicobacter. 2018;23(3):e12486.

    PubMed  PubMed Central  Google Scholar 

  22. Li HJ, Fang EH, Wang JQ, Zheng LD, Tong QS. Helicobacter pylori infection facilitates the expression of resistin-like molecule beta in gastric carcinoma and precursor lesions. Curr Med Sci. 2020;40(1):95–103.

    CAS  PubMed  Google Scholar 

  23. Pandey R, Misra V, Misra SP, Dwivedi M, Misra A. Helicobacter pylori infection and a P53 codon 72 single nucleotide polymorphism: a reason for an unexplained Asian enigma. Asian Pac J Cancer Prev. 2014;15(21):9171–6.

    PubMed  Google Scholar 

  24. Ouyang Y, Liu G, Xu W, Yang Z, Li N, Xie C, et al. Helicobacter pylori induces epithelial-mesenchymal transition in gastric carcinogenesis via the AKT/GSK3β signaling pathway. Oncol Lett. 2021;21(2):1.

    Google Scholar 

  25. Alaoui Boukhris S, Amarti A, El Rhazi K, El Khadir M, Benajah D-A, Ibrahimi SA, et al. Helicobacter pylori genotypes associated with gastric histo-pathological damages in a Moroccan population. PLoS One. 2013;8(12):e82646.

    PubMed  PubMed Central  Google Scholar 

  26. Gunaletchumy SP, Seevasant I, Tan MH, Croft LJ, Mitchell HM, Goh KL, et al. Helicobacter pylori genetic diversity and gastro-duodenal diseases in Malaysia. Sci Rep. 2014;4(1):1–9.

    Google Scholar 

  27. Raei N, Latifi-Navid S, Zahri S. Helicobacter pylori cag pathogenicity island cagL and orf17 genotypes predict risk of peptic ulcerations but not gastric cancer in Iran. Asian Pac J Cancer Prev. 2015;16(15):6645–50.

    PubMed  Google Scholar 

  28. Abdi E, Latifi-Navid S, Yazdanbod A, Zahri S. Helicobacter pylori babA2 positivity predicts risk of gastric cancer in Ardabil, a very high-risk area in Iran. Asian Pac J Cancer Prev. 2016;17(2):733–8.

    PubMed  Google Scholar 

  29. Ansari S, Kabamba ET, Shrestha PK, Aftab H, Myint T, Tshering L, et al. Helicobacter pylori bab characterization in clinical isolates from Bhutan, Myanmar, Nepal and Bangladesh. PLoS One. 2017;12(11):e0187225.

    PubMed  PubMed Central  Google Scholar 

  30. Mohammadi M, Abadi ATB, Rahimi F, Forootan M. Helicobacter heilmannii colonization is associated with high risk for gastritis. Arch Med Res. 2019;50(7):423–7.

    CAS  PubMed  Google Scholar 

  31. Yeh YC, Kuo HY, Chang WL, Yang HB, Lu CC, Cheng H-C, et al. H. pylori isolates with amino acid sequence polymorphisms as presence of both HtrA-L171 & CagL-Y58/E59 increase the risk of gastric cancer. J Biomed Sci. 2019;26(1):1–8.

    CAS  Google Scholar 

  32. Hernandez EG, Partida-Rodriguez O, Camorlinga-Ponce M, Nieves-Ramirez M, Ramos-Vega I, Torres J, et al. Genotype B of killer cell immunoglobulin-like receptor is related with gastric cancer lesions. Sci Rep. 2018;8(1):1–9.

    Google Scholar 

  33. Zeng HM, Pan KF, Zhang Y, Zhang L, Ma JL, Zhou T, et al. Genetic Variants of Toll-Like Receptor 2 and 5, Helicobacter Pylori Infection, and Risk of Gastric Cancer and Its Precursors in a Chinese PopulationPolymorphisms of Toll-Like Receptors and Gastric Cancer and Its Precursors. Cancer Epidemiol Biomark Prev. 2011;20(12):2594–602.

    CAS  Google Scholar 

  34. Boonyanugomol W, Kongkasame W, Palittapongarnpim P, Baik SC, Jung MH, Shin MK, et al. Genetic variation in the cag pathogenicity island of Helicobacter pylori strains detected from gastroduodenal patients in Thailand. Braz J Microbiol. 2020;51(3):1093–101.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang L, Xin Y, Zhou J, Tian Z, Liu C, Yu X, et al. Gastric mucosa-associated microbial signatures of early gastric cancer. Front Microbiol. 2020;11:1548.

    PubMed  PubMed Central  Google Scholar 

  36. Sakitani K, Hirata Y, Suzuki N, Shichijo S, Yanai A, Serizawa T, et al. Gastric cancer diagnosed after Helicobacter pylori eradication in diabetes mellitus patients. BMC Gastroenterol. 2015;15(1):1–7.

    Google Scholar 

  37. Sekikawa A, Fukui H, Sada R, Fukuhara M, Marui S, Tanke G, et al. Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer. J Gastroenterol. 2016;51(1):35–42.

    CAS  PubMed  Google Scholar 

  38. Pakbaz Z, Shirazi MH, Ranjbar R, Gholi MK, Aliramezani A, Malekshahi ZV. Frequency *scent Medical Journal. 2013;15(9):767.

  39. Shadman M, Rajabian Z, Ajami A, Hussein-Nattaj H, Rafiei A, Hosseini V, et al. Frequency of γδ T cells and invariant natural killer T cells in Helicobacter pylori-infected patients with peptic ulcer and gastric cancer. Iran J Allergy Asthma Immunol. 2015;14:493–501.

    PubMed  Google Scholar 

  40. Archampong TN, Asmah RH, Wiredu EK, Gyasi RK, Nkrumah KN. Factors associated with gastro-duodenal disease in patients undergoing upper GI endoscopy at the Korle-Bu Teaching Hospital, Accra, Ghana. Afr Health Sci. 2016;16(2):611–9.

    PubMed  PubMed Central  Google Scholar 

  41. Kobayashi S, Ogura M, Suzawa N, Horiki N, Katsurahara M, Ogura T, et al. 18F-FDG uptake in the stomach on screening PET/CT: Value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Med Imaging. 2016;16(1):1–8.

    Google Scholar 

  42. Xie C, Xu LY, Yang Z, Cao XM, Li W, Lu NH. Expression of γH2AX in various gastric pathologies and its association with Helicobacter pylori infection. Oncol Lett. 2014;7(1):159–63.

    CAS  PubMed  Google Scholar 

  43. Deng N, Liu JW, Sun LP, Xu Q, Duan ZP, Dong NN, et al. Expression of XPG protein in the development, progression and prognosis of gastric cancer. PLoS One. 2014;9(9):e108704.

    PubMed  PubMed Central  Google Scholar 

  44. Shi YY, Chen M, Zhang YX, Zhang J, Ding SG. Expression of three essential antioxidants of Helicobacter pylori in clinical isolates. J Zhejiang Univ Sci B. 2014;15(5):500–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Zabaglia LM, Sallas ML, Santos MPd, Orcini WA, Peruquetti RL, Constantino DH, et al. Expression of miRNA-146a, miRNA-155, IL-2, and TNF-α in inflammatory response to Helicobacter pylori infection associated with cancer progression. Ann Hum Genet. 2018;82(3):135–42.

    CAS  PubMed  Google Scholar 

  46. Szkaradkiewicz A, Karpiński TM, Linke K, Majewski P, Rożkiewicz D, Goślińska-Kuźniarek O. Expression of cagA, virB/D complex and/or vacA genes in Helicobacter pylori strains originating from patients with gastric diseases. PLoS One. 2016;11(2):e0148936.

    PubMed  PubMed Central  Google Scholar 

  47. Jorge YC, Mataruco MM, Araújo LP, Rossi AFT, De Oliveira JG, Valsechi MC, et al. Expression of annexin-A1 and galectin-1 anti-inflammatory proteins and mRNA in chronic gastritis and gastric cancer. Mediators Inflamm. 2013;2013:152860.

    PubMed  PubMed Central  Google Scholar 

  48. Taghizadeh S, Sankian M, Ajami A, Tehrani M, Hafezi N, Mohammadian R, et al. Expression levels of vascular endothelial growth factors a and C in patients with peptic ulcers and gastric cancer. J Gastric Cancer. 2014;14(3):196–203.

    PubMed  PubMed Central  Google Scholar 

  49. Yan X, Hu X, Duan B, Zhang X, Pan J, Fu J, et al. Exploration of endoscopic findings and risk factors of early gastric cancer after eradication of Helicobacter pylori. Scand J Gastroenterol. 2021;56(3):356–62.

    CAS  PubMed  Google Scholar 

  50. Anwar M, Youssef A, Sheta M, Zaki A, Bernaba N, El Toukhi M. Evaluation of specific biochemical indicators of Helicobactepylori-associated gastric cancer in Egypt. East Mediterr Health J. 2012;18(5):501–7.

    CAS  PubMed  Google Scholar 

  51. Park CH, Lee AR, Lee YR, Eun CS, Lee SK, Han DS. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24(1):e12547.

    PubMed  Google Scholar 

  52. Toyoshima O, Yamaji Y, Yoshida S, Matsumoto S, Yamashita H, Kanazawa T, et al. Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication. Surg Endosc. 2017;31(5):2140–8.

    PubMed  Google Scholar 

  53. Kobayashi S, Joshita S, Yamamoto C, Yanagisawa T, Miyazawa T, Miyazawa M, et al. Efficacy and safety of eradication therapy for elderly patients with helicobacter pylori infection. Medicine. 2019;98(30):e16619.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Boonyanugomol W, Kongkasame W, Palittapongarnpim P, Jung M, Shin M-K, Kang H-L, et al. Distinct Genetic Variation of Helicobacter pylori cagA, vacA, oipA, and sabA Genes in Thai and Korean Dyspeptic Patients. Microbiol Biotechnol Lett. 2018;46(3):261–8.

    CAS  Google Scholar 

  55. Pandey A, Tripathi SC, Shukla S, Mahata S, Vishnoi K, Misra SP, et al. Differentially localized survivin and STAT3 as markers of gastric cancer progression: Association with Helicobacter pylori. Cancer Rep. 2018;1(1):e1004.

    Google Scholar 

  56. Zhao Q, Song C, Wang K, Li D, Yang Y, Liu D, et al. Prevalence of Helicobacter pylori babA, oipA, sabA, and homB genes in isolates from Chinese patients with different gastroduodenal diseases. Med Microbiol Immunol. 2020;209(5):565–77.

    CAS  PubMed  Google Scholar 

  57. Abu-Taleb AM, Abdelattef RS, Abdel-Hady AA, Omran FH, El-Korashi LA, El-hady AA, et al. Prevalence of Helicobacter pylori cagA and iceA genes and their association with gastrointestinal diseases. Int J Microbiol. 2018;2018:4809093.

    PubMed  PubMed Central  Google Scholar 

  58. Saber T, Ghonaim MM, Yousef AR, Khalifa A, Qurashi HA, Shaqhan M, et al. Association of Helicobacter pylori cagA gene with gastric cancer and peptic ulcer in saudi patients. J Microbiol Biotechnol. 2015;25(7):1146–53.

    CAS  PubMed  Google Scholar 

  59. Matsunari O, Shiota S, Suzuki R, Watada M, Kinjo N, Murakami K, et al. Association between Helicobacter pylori virulence factors and gastroduodenal diseases in Okinawa, Japan. J Clin Microbiol. 2012;50(3):876–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Ghoshal U, Kumar S, Jaiswal V, Tripathi S, Mittal B, Ghoshal UC. Association of microsomal epoxide hydrolase exon 3 Tyr113His and exon 4 His139Arg polymorphisms with gastric cancer in India. Indian J Gastroenterol. 2013;32(4):246–52.

    PubMed  Google Scholar 

  61. Amiri RM, Tehrani M, Taghizadeh S, Shokri-Shirvani J, Fakheri H, Ajami A. Association of nucleotide-binding oligomerization domain receptors with peptic ulcer and gastric cancer. Iran J Allergy Asthma Immunol. 2016;15:355–62.

    Google Scholar 

  62. Sheikh AF, Yadyad MJ, Goodarzi H, Hashemi SJ, Aslani S, Assarzadegan M-A, et al. CagA and vacA allelic combination of Helicobacter pylori in gastroduodenal disorders. Microb Pathog. 2018;122:144–50.

    CAS  PubMed  Google Scholar 

  63. El Khadir M, Boukhris SA, Zahir SO, Benajah D-A, Ibrahimi SA, Chbani L, et al. CagE, cagA and cagA 3′ region polymorphism of Helicobacter pylori and their association with the intra-gastric diseases in Moroccan population. Diagn Microbiol Infect Dis. 2021;100(3):115372.

    PubMed  Google Scholar 

  64. Park YM, Kim J-H, Baik SJ, Park JJ, Youn YH, Park H. Clinical risk assessment for gastric cancer in asymptomatic population after a health check-up: an individualized consideration of the risk factors. Medicine. 2016;95(44):e5351.

    PubMed  PubMed Central  Google Scholar 

  65. Kawamura M, Sekine H, Abe S, Shibuya D, Kato K, Masuda T. Clinical significance of white gastric crypt openings observed via magnifying endoscopy. World J Gastroenterol. 2013;19(48):9392.

    PubMed  PubMed Central  Google Scholar 

  66. Raza Y, Khan A, Khan AI, Khan S, Akhter S, Mubarak M, et al. Combination of interleukin 1 polymorphism and Helicobacter pylori infection: an increased risk of gastric cancer in Pakistani population. Pathol Oncol Res. 2017;23(4):873–80.

    CAS  PubMed  Google Scholar 

  67. Dos Santos MP, Pereira JN, De Labio RW, Carneiro LC, Pontes JC, Barbosa MS, et al. Decrease of miR-125a-5p in gastritis and gastric cancer and its possible association with H. pylori. J Gastrointest Cancer. 2021;52(2):569–74.

    PubMed  Google Scholar 

  68. Tomatari FH, Mobarez AM, Amini M, Hosseini D, Abadi ATB. Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Dyspeptic Patients in Iran. Iran Red Crescent Med J. 2010;12(4):409.

    Google Scholar 

  69. Guo XY, Dong L, Qin B, Jiang J, Shi AM. Decreased expression of gastrokine 1 in gastric mucosa of gastric cancer patients. World J Gastroenterol. 2014;20(44):16702.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Shadifar M, Ataee R, Ataie A, HeydariGorgi AM, NasriNasrabadi N, Nouri S. Genetic and molecular aspects of Helicobacter pylori in gastritis, pre- cancerous conditions and gastric adenocrcinoma. Gastroenterol Hepatol Bed Bench. 2015;8(Suppl 1):S15–22. Spring.

    PubMed  PubMed Central  Google Scholar 

  71. Asha S, Kumarreddy R, Ramanathan T, Sudhakar N. Survey, isolation, biochemical characterization, and identification of helicobacter pylori from gastric patient biopsy. Asian J Pharm Clin Res. 2017:411–6.

  72. Cremniter J, Bodet C, Tougeron D, Dray X, Guilhot J, Jégou JF, et al. Th-17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of Helicobacter pylori-infected patients independently of their clinical outcomes. Helicobacter. 2018;23(3):e12479.

    PubMed  Google Scholar 

  73. Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, et al. The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations. Helicobacter. 2018;23(2):e12464.

    PubMed  Google Scholar 

  74. Bakhti SZ, Latifi-Navid S, Zahri S. Unique constellations of five polymorphic sites of Helicobacter pylori vacA and cagA status associated with risk of gastric cancer. Infect Genet Evol. 2020;79:104167.

    CAS  PubMed  Google Scholar 

  75. Vannarath S, Vilaichone R-K, Rasachak B, Mairiang P, Yamaoka Y, Shiota S, et al. Virulence genes of Helicobacter pylori in gastritis, peptic ulcer and gastric cancer in Laos. Asian Pac J Cancer Prev. 2014;15(20):9027–31.

    PubMed  Google Scholar 

  76. Taghvaei T, TalebiBezminAbadi A, Ghasemzadeh A, Naderi BK, MohabbatiMobarez A. Prevalence of horB gene among the Helicobacter pylori strains isolated from dyspeptic patients: first report from Iran. Intern Emerg Med. 2012;7(6):505–8.

    PubMed  Google Scholar 

  77. Raza Y, Ahmed A, Khan A, Chishti AA, Akhter SS, Mubarak M, et al. Helicobacter pylori severely reduces expression of DNA repair proteins PMS2 and ERCC1 in gastritis and gastric cancer. DNA Repair. 2020;89:102836.

    CAS  PubMed  Google Scholar 

  78. Wang TR, Peng JC, Qiao YQ, Zhu MM, Zhao D, Shen J, et al. Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis. Int J Clin Exp Pathol. 2014;7(10):6950.

    PubMed  PubMed Central  Google Scholar 

  79. Kumar S, Metz DC, Ginsberg GG, Kaplan DE, Goldberg DS. Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection. Aliment Pharmacol Ther. 2020;51(8):781–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Nishikawa I, Kato J, Terasoma S, Matsutani H, Tamaki H, Tamaki T, et al. Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication. JGH Open. 2018;2(3):80–6.

    PubMed  PubMed Central  Google Scholar 

  81. Sadjadi A, Derakhshan MH, Yazdanbod A, Boreiri M, Parsaeian M, Babaei M, et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. Int J Cancer. 2014;134(1):181–8.

    PubMed  Google Scholar 

  82. Abe T, Kodama M, Murakami K, Matsunari O, Mizukami K, Inoue K, et al. Impact of Helicobacter pylori CagA diversity on gastric mucosal damage: An immunohistochemical study of East-Asian-type CagA. J Gastroenterol Hepatol. 2011;26(4):688–93.

    PubMed  Google Scholar 

  83. de la Cruz-Herrera CF, Flores-Luna L, Gutierrez-Xicotencatl L, Chihu-Amparan L, Sanchez-Aleman MA, Lazcano-Ponce E, et al. IgG2 response and low IgG titre specific to Helicobacter pylori CagA as serological markers for gastric cancer. J Med Microbiol. 2013;62(4):591–8.

    PubMed  Google Scholar 

  84. Batista SA, Rocha GA, Rocha A, Saraiva IE, Cabral MM, Oliveira RC, et al. Higher number of Helicobacter pylori CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. BMC Microbiol. 2011;11(1):1–7.

    Google Scholar 

  85. Cavalcante MQdF, Silva CIS, Braga-Neto MB, Fialho ABC, NunesFialho A, Barbosa AMC, et al. Helicobacter pylori vacA and cagA genotypes in patients from northeastern Brazil with upper gastrointestinal diseases. Mem Inst Oswaldo Cruz. 2012;107:561–3.

    PubMed  Google Scholar 

  86. Vohlonen I, Pukkala E, Malila N, Härkönen M, Hakama M, Koistinen V, et al. Risk of gastric cancer in Helicobacter pylori infection in a 15-year follow-up. Scand J Gastroenterol. 2016;51(10):1159–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Salih BA, Gucin Z, Bayyurt N. A study on the effect of Helicobacter pylori infection on p53 expression in gastric cancer and gastritis tissues. J Infect Dev Ctries. 2013;7(09):651–7.

    CAS  PubMed  Google Scholar 

  88. Toyoda K, Furusyo N, Ihara T, Ikezaki H, Urita Y, Hayashi J. Serum pepsinogen and Helicobacter pylori infection—a Japanese population study. Eur J Clin Microbiol Infect Dis. 2012;31(9):2117–24.

    CAS  PubMed  Google Scholar 

  89. Shrestha R, Koirala K, Raj KS, Batajoo KH. Helicobacter pylori infection among patients with upper gastrointestinal symptoms: prevalence and relation to endoscopy diagnosis and histopathology. J Fam Med Prim Care. 2014;3(2):154.

    Google Scholar 

  90. Gantuya B, Oyuntsetseg K, Bolor D, Erdene-Ochir Y, Sanduijav R, Davaadorj D, et al. Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area. Gastric Cancer. 2019;22(1):104–12.

    CAS  PubMed  Google Scholar 

  91. Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E, et al. The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies. Lupus. 2018;27(6):899–912.

    CAS  PubMed  Google Scholar 

  92. Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E, et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018;25(10):1155–64.

    PubMed  Google Scholar 

  93. Haddadi MH, Bazargani A, Khashei R, Fattahi MR, Lankarani KB, Moini M, et al. Different distribution of Helicobacter pylori EPIYA-cagA motifs and dupA genes in the upper gastrointestinal diseases and correlation with clinical outcomes in iranian patients. Gastroenterol Hepatol Bed Bench. 2015;8(Suppl1):S37.

    PubMed  PubMed Central  Google Scholar 

  94. Shibukawa N, Ouchi S, Wakamatsu S, Wakahara Y, Kaneko A. Gastric xanthoma is correlated with early gastric cancer of previously Helicobacter pylori-infected gastric mucosa. JGH Open. 2021;5(2):249–52.

    PubMed  Google Scholar 

  95. Asl HM, Badamchi A, Javadinia S, Khaleghi S, Tehraninia L, Saedi S, et al. Prevalence of Helicobacter pylori vacA, cagA, cagE1, cagE2, dupA and oipA genotypes in patients with gastrointestinal diseases. Acta Medica Iranica. 2020:310–7.

  96. Khan A, Farooqui A, Raza Y, Rasheed F, Manzoor H, Akhtar SS, et al. Prevalence, diversity and disease association of Helicobacter pylori in dyspeptic patients from Pakistan. J Infect Dev Ctries. 2013;7(03):220–8.

    PubMed  Google Scholar 

  97. Santos J, Ladeira M, Pedrazzoli J Jr, Ribeiro M. Relationship of IL-1 and TNF-α polymorphisms with Helicobacter pylori in gastric diseases in a Brazilian population. Braz J Med Biol Res. 2012;45:811–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. GholizadeTobnagh S, Bakhti SZ, Navid SL, Zahri S, Bakhti FS. Role of plasticity region genes and cagE gene of cagPAI of Helicobacter pylori in development of gastrointestinal (GI) diseases. Asian Pac J Cancer Prev. 2017;18(1):43.

    PubMed  PubMed Central  Google Scholar 

  99. Wei G-C, Chen J, Liu A-Y, Zhang M, Liu X-J, Liu D, et al. Prevalence of Helicobacter pylori vacA, cagA and iceA genotypes and correlation with clinical outcome. Exp Ther Med. 2012;4(6):1039–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Dabiri H, Jafari F, Baghaei K, Shokrzadeh L, Abdi S, Pourhoseingholi MA, et al. Prevalence of Helicobacter pylori vacA, cagA, cagE, oipA, iceA, babA2 and babB genotypes in Iranian dyspeptic patients. Microb Pathog. 2017;105:226–30.

    CAS  PubMed  Google Scholar 

  101. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. J Am Coll Gastroenterol| ACG. 2013;108(2):208–15.

    Google Scholar 

  102. Vinagre IDF, Queiroz ALd, Silva Júnior MRd, Vinagre RMDF, Martins LC. Helicobacter pylori infection in patients with different gastrointestinal diseases from northern Brazil. Arq Gastroenterol. 2015;52:266–71.

    PubMed  Google Scholar 

  103. Gücin Z, Çakmak T, Bayyurt N, Salih B. Helicobacter pylori infection and relationship with gastric epithelial cell proliferation and apoptosis. Turk J Med Sci. 2013;43(5):739–46.

    Google Scholar 

  104. Sheikhani MA, Alkarbuly TA, Muhammad PT. Helicobacter Pylori infection among Dyspeptic Patients Referred for Endoscopy. Zanco J Med Sci. 2010;14(1 Special):37–43.

    Google Scholar 

  105. Leylabadlo HE, Yekani M, Ghotaslou R. Helicobacter pylori hopQ alleles (type I and II) in gastric cancer. Biomed Rep. 2016;4(5):601–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Khamis AS, Al-Jibouri LF, Al-Marzoqi AH, Shalan AA, Al-Taee ZM, Al Morshdi SF, et al. Helicobacter pylori genotype as predicts risk of (ulcer disease, gastric cancer, non-ulcer dyspepsia); role of some genes mediated signaling in infection. J Pharm Sci Res. 2018;10(6):1373–6.

    CAS  Google Scholar 

  107. Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67(12):2092–6.

    PubMed  Google Scholar 

  108. Horie R, Handa O, Ando T, Ose T, Murakami T, Suzuki N, et al. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter. 2020;25(4):e12698.

    CAS  PubMed  Google Scholar 

  109. Kim HJ, Kim N, Park JH, Choi S, Shin CM, Lee OJ. Helicobacter pylori eradication induced constant decrease in interleukin-1B expression over more than 5 years in patients with gastric cancer and dysplasia. Gut and Liver. 2020;14(6):735.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Shukla SK, Prasad KN, Tripathi A, Jaiswal V, Khatoon J, Ghsohal UC, et al. Helicobacter pylori cagL amino acid polymorphisms and its association with gastroduodenal diseases. Gastric Cancer. 2013;16(3):435–9.

    CAS  PubMed  Google Scholar 

  111. Cherati MR, Shokri-Shirvani J, Karkhah A, Rajabnia R, Nouri HR. Helicobacter pylori cagL amino acid polymorphism D58E59 pave the way toward peptic ulcer disease while N58E59 is associated with gastric cancer in north of Iran. Microb Pathog. 2017;107:413–8.

    CAS  PubMed  Google Scholar 

  112. El Khadir M, Boukhris SA, Benajah D-A, Ibrahimi SA, Chbani L, Bouguenouch L, et al. Helicobacter pylori CagA EPIYA-C motifs and gastric diseases in Moroccan patients. Infect Genet Evol. 2018;66:120–9.

    PubMed  Google Scholar 

  113. Ortiz V, Estevez-Ordonez D, Montalvan-Sanchez E, Urrutia-Argueta S, Israel D, Krishna US, et al. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low-resource Central America setting. Helicobacter. 2019;24(4):e12595.

    PubMed  PubMed Central  Google Scholar 

  114. Sheu SM, Sheu BS, Chiang WC, Kao CY, Wu HM, Yang HB, et al. H. pylori clinical isolates have diverse babAB genotype distributions over different topographic sites of stomach with correlation to clinical disease outcomes. BMC Microbiol. 2012;12(1):1–9.

    Google Scholar 

  115. Yeh YC, Chang WL, Yang HB, Cheng HC, Wu JJ, Sheu BSH. pylori cagL amino acid sequence polymorphism Y58E59 induces a corpus shift of gastric integrin α5β1 related with gastric carcinogenesis. Mol Carcinog. 2011;50(10):751–9.

    CAS  PubMed  Google Scholar 

  116. Goudarzi H, Seyedjavadi SS, Fazeli M, Azad M, Goudarzi M. Genotyping of peroxisome proliferator-activated receptor gamma in iranian patients with Helicobacter pylori infection. Asian Pac J Cancer Prev. 2015;16(13):5219–23.

    PubMed  Google Scholar 

  117. Phan TN, Santona A, Tran TNH, Cappuccinelli P, Rubino S, Paglietti B. Genotyping of Helicobacter pylori shows high diversity of strains circulating in central Vietnam. Infect Genet Evol. 2017;52:19–25.

    CAS  PubMed  Google Scholar 

  118. Al-Sabary AH, Razzaq MSA, Wtwt MA. Genotyping of Helicobacter pylori isolated from Iraqi patient with upper gastrointestinal disease. J Glob Pharma Technol. 2017;9(9):121–7.

    Google Scholar 

  119. Ranjbar R, Chehelgerdi M. Genotyping and antibiotic resistance properties of Helicobacter pylori strains isolated from human and animal gastric biopsies. Infect Drug Resist. 2018;11:2545.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Blanchard TG, Czinn SJ, Correa P, Nakazawa T, Keelan M, Morningstar L, et al. Genome sequences of 65 Helicobacter pylori strains isolated from asymptomatic individuals and patients with gastric cancer, peptic ulcer disease, or gastritis. Pathog Dis. 2013;68(2):39–43.

    CAS  PubMed  Google Scholar 

  121. Ogawa H, Iwamoto A, Tanahashi T, Okada R, Yamamoto K, Nishiumi S, et al. Genetic variants of Helicobacter pylori type IV secretion system components CagL and CagI and their association with clinical outcomes. Gut Pathog. 2017;9(1):1–12.

    Google Scholar 

  122. Boonyanugomol W, Rukseree K, Kongkasame W, Palittapongarnpim P, Baik S-C, Manwong M. Genetic Polymorphisms of CXCL8 (− 251) Are Associated with the Susceptibility of Helicobacter pylori Infection Increased the Risk of Inflammation and Gastric Cancer in Thai Gastroduodenal Patients. Iran J Allergy Asthma Immunol. 2019;18:393–401.

    PubMed  Google Scholar 

  123. Ghoshal U, Tripathi S, Kumar S, Mittal B, Chourasia D, Kumari N, et al. Genetic polymorphism of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP2E1 genes modulate susceptibility to gastric cancer in patients with Helicobacter pylori infection. Gastric Cancer. 2014;17(2):226–34.

    CAS  PubMed  Google Scholar 

  124. Farzi N, Yadegar A, Aghdaei HA, Yamaoka Y, Zali MR. Genetic diversity and functional analysis of oipA gene in association with other virulence factors among Helicobacter pylori isolates from Iranian patients with different gastric diseases. Infect Genet Evol. 2018;60:26–34.

    CAS  PubMed  Google Scholar 

  125. Yadegar A, Mohabati Mobarez A, Zali MR. Genetic diversity and amino acid sequence polymorphism in Helicobacter pylori CagL hypervariable motif and its association with virulence markers and gastroduodenal diseases. Cancer Med. 2019;8(4):1619–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Hashemi SJ, Sheikh AF, Goodarzi H, Yadyad MJ, Seyedian SS, Aslani S, et al. Genetic basis for metronidazole and clarithromycin resistance in Helicobacter pylori strains isolated from patients with gastroduodenal disorders. Infect Drug Resist. 2019;12:535.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. Kupcinskas J, Wex T, Link A, Leja M, Bruzaite I, Steponaitiene R, et al. Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer. PLoS One. 2014;9(1):e87467.

    PubMed  PubMed Central  Google Scholar 

  128. Oh JH, Rhyu MG, Kim SI, Yun MR, Shin JH, Hong SJ. Gastric mucosal atrophy impedes housekeeping gene methylation in gastric cancer patients. Cancer Res Treat. 2019;51(1):267–79.

    CAS  PubMed  Google Scholar 

  129. Boreiri M, Samadi F, Etemadi A, Babaei M, Ahmadi E, Sharifi AH, et al. Gastric cancer mortality in a high incidence area: long-term follow-up of Helicobacter pylori-related precancerous lesions in the general population. Arch Iran Med. 2013;16(6):343.

    PubMed  PubMed Central  Google Scholar 

  130. Sedarat Z, Khashei R, Shirzad H, Bagheri N, Sadeghiani M, Shahi H, et al. Frequency of helicobacter pylori hopQI, hopQII and sabA genes among Iranian patients with gastroduodenal diseases. Jundishapur J Microbiol. 2018.

  131. Shin CM, Kim N, Chang H, Kim JS, Lee DH, Jung HC. Follow-up study on CDX1 and CDX2 mRNA expression in noncancerous gastric mucosae after Helicobacter pylori eradication. Dig Dis Sci. 2016;61(4):1051–9.

    CAS  PubMed  Google Scholar 

  132. Yu XW, Xu Q, Xu Y, Gong YH, Yuan Y. Expression of the E-cadherin/β-catenin/tcf-4 pathway in gastric diseases with relation to Helicobacter pylori infection: clinical and pathological implications. Asian Pac J Cancer Prev. 2014;15(1):215–20.

    CAS  PubMed  Google Scholar 

  133. Khatoon J, Prasad KN, Rai RP, Shukla SK, Krishnani N, Ghoshal UC. Expression levels of A disintegrin and metalloproteases (ADAMs), and Th17-related cytokines and their association with Helicobacter pylori infection in patients with gastroduodenal diseases. Pathog Dis. 2018;76(8):fty078.

    CAS  Google Scholar 

  134. Vilar e Silva A, Junior MRdS, Vinagre RMDF, Santos KN, da Costa RAA, Fecury AA, et al. Evaluation of the pattern of EPIYA motifs in the Helicobacter pylori cagA gene of patients with gastritis and gastric adenocarcinoma from the Brazilian Amazon region. Int J Bacteriol. 2014;2014:418063.

    PubMed  PubMed Central  Google Scholar 

  135. Beheshtirouy S, Eyvazi S, Tarhriz V. Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients. J Gastrointest Cancer. 2021;52(1):207–11.

    CAS  PubMed  Google Scholar 

  136. Shukla SK, Prasad K, Tripathi A, Singh A, Saxena A, Ghoshal UC, et al. Epstein-Barr virus DNA load and its association with Helicobacter pylori infection in gastroduodenal diseases. Braz J Infect Dis. 2011;15:583–90.

    CAS  PubMed  Google Scholar 

  137. Spulber G, Mateescu R, Radu FI, Jinga M, Nuţă P, Costache RS, et al. Endoscopic faces of Helicobacter Pylori infection. RJMM. 2015:34.

  138. Sugimoto M, Ban H, Ichikawa H, Sahara S, Otsuka T, Inatomi O, et al. Efficacy of the Kyoto classification of gastritis in identifying patients at high risk for gastric cancer. Intern Med. 2017;56(6):579–86.

    PubMed  PubMed Central  Google Scholar 

  139. Leung WK, Wong IO, Cheung KS, Yeung KF, Chan EW, Wong AY, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155(1):67–75.

    PubMed  Google Scholar 

  140. Watari J, Ito C, Shimoda T, Tomita T, Oshima T, Fukui H, et al. DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: analysis of the effects of H. pylori eradication and long-term aspirin use. Sci Rep. 2019;9(1):1–10.

    Google Scholar 

  141. Nam SY, Park BJ, Nam JH, Kook MC. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc. 2019;90(3):448–56. e1.

    PubMed  Google Scholar 

  142. Sallas ML, Zapparoli D, Dos Santos MP, Pereira JN, Orcini WA, Peruquetti RL, et al. Dysregulated Expression of Apoptosis-Associated Genes and MicroRNAs and Their Involvement in Gastric Carcinogenesis. J Gastrointest Cancer. 2021;52(2):625–33.

    CAS  PubMed  Google Scholar 

  143. Queiroz DM, Rocha GA, Rocha AM, Moura SB, Saraiva IE, Gomes LI, et al. dupA polymorphisms and risk of Helicobacter pylori-associated diseases. Int J Med Microbiol. 2011;301(3):225–8.

    CAS  PubMed  Google Scholar 

  144. Sun L, Talarico S, Yao L, He L, Self S, You Y, et al. Droplet digital PCR-based detection of clarithromycin resistance in Helicobacter pylori isolates reveals frequent heteroresistance. J Clin Microbiol. 2018;56(9):e00019–e118.

    CAS  PubMed  PubMed Central  Google Scholar 

  145. Jiang JX, Liu Q, Mao XY, Zhang HH, Zhang GX, Xu SF. Downward trend in the prevalence of Helicobacter pylori infections and corresponding frequent upper gastrointestinal diseases profile changes in Southeastern China between 2003 and 2012. Springerplus. 2016;5(1):1–9.

    Google Scholar 

  146. Hu Y, Liu JP, Li XY, Cai Y, He C, Li NS, et al. Downregulation of tumor suppressor RACK1 by Helicobacter pylori infection promotes gastric carcinogenesis through the integrin β-1/NF-κB signaling pathway. Cancer Lett. 2019;450:144–54.

    CAS  PubMed  Google Scholar 

  147. Ferraz MA, Zabaglia LM, Pereira WN, Orcini WA, de Labio RW, Neto AC, et al. Downregulated expression of e-cadherin and tp53 in patients with gastric diseases: the involvement of h. Pylori infection and its virulence markers. J Gastrointest Cancer. 2016;47(1):20–6.

    CAS  PubMed  Google Scholar 

  148. Tahara S, Tahara T, Horiguchi N, Kato T, Shinkai Y, Yamashita H, et al. DNA methylation accumulation in gastric mucosa adjacent to cancer after Helicobacter pylori eradication. Int J Cancer. 2019;144(1):80–8.

    CAS  PubMed  Google Scholar 

  149. Vaziri F, Peerayeh SN, Alebouyeh M, Mirzaei T, Yamaoka Y, Molaei M, et al. Diversity of Helicobacter pylori genotypes in Iranian patients with different gastroduodenal disorders. World J Gastroenterol. 2013;19(34):5685.

    CAS  PubMed  PubMed Central  Google Scholar 

  150. Ono T, Cruz M, Nagashima H, Subsomwong P, Akada J, Matsumoto T, et al. Discovery of unique African Helicobacter pylori CagA-multimerization motif in the Dominican Republic. World J Gastroenterol. 2020;26(45):7118.

    PubMed  PubMed Central  Google Scholar 

  151. Link A, Schirrmeister W, Langner C, Varbanova M, Bornschein J, Wex T, et al. Differential expression of microRNAs in preneoplastic gastric mucosa. Sci Rep. 2015;5(1):1–8.

    Google Scholar 

  152. Casarotto M, Pratesi C, Bidoli E, Maiero S, Magris R, Steffan A, et al. Differential Helicobacter pylori Plasticity in the gastric niche of subjects at increased gastric cancer risk. Pathogens. 2019;8(2):65.

    CAS  PubMed  PubMed Central  Google Scholar 

  153. Chomvarin C, Phusri K, Sawadpanich K, Mairiang P, Namwat W, Wongkham C, et al. Prevalence of cagA EPIYA motifs in Helicobacter pylori among dyspeptic patients in northeast Thailand. Southeast Asian J Trop Med Public Health. 2012;43(1):105.

    CAS  PubMed  Google Scholar 

  154. Bilgiç F, Gerçeker E, Boyacıoğlu SÖ, Kasap E, Demirci U, Yıldırım H, et al. Potential role of chromatin remodeling factor genes in atrophic gastritis/gastric cancer risk. Turk J Gastroenterol. 2018;29(4):427.

    PubMed  PubMed Central  Google Scholar 

  155. Chiu YM, Tsai CL, Kao JT, Hsieh CT, Shieh DC, Lee YJ, et al. PD-1 and PD-L1 up-regulation promotes T-cell apoptosis in gastric adenocarcinoma. Anticancer Res. 2018;38(4):2069–78.

    CAS  PubMed  Google Scholar 

  156. TalebiBezminAbadi A, Ghasemzadeh A, MohabatiMobarez A. Low frequency of cagA-positive Helicobacter pylori strains isolated from Iranian patients with MALT lymphoma. Intern Emerg Med. 2013;8(1):49–53.

    Google Scholar 

  157. Hnatyszyn A, Wielgus K, Kaczmarek-Rys M, Skrzypczak-Zielinska M, Szalata M, Mikolajczyk-Stecyna J, et al. Interleukin-1 gene polymorphisms in chronic gastritis patients infected with Helicobacter pylori as risk factors of gastric cancer development. Arch Immunol Ther Exp. 2013;61(6):503–12.

    CAS  Google Scholar 

  158. Abadi ATB, Taghvaei T, Wolfram L, Kusters JG. Infection with Helicobacter pylori strains lacking dupA is associated with an increased risk of gastric ulcer and gastric cancer development. J Med Microbiol. 2012;61(1):23–30.

    CAS  Google Scholar 

  159. Ohkusa T, Miwa H, Nomura T, Asaoka D, Kurosawa A, Sakamoto N, et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients. Aliment Pharmacol Ther. 2004;20:25–32.

    PubMed  Google Scholar 

  160. Lahner E, Bernardini G, Possenti S, Renzone G, Scaloni A, Santucci A, et al. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer. Int J Med Microbiol. 2011;301(2):125–32.

    CAS  PubMed  Google Scholar 

  161. Tanaka A, Kamada T, Inoue K, Shiotani A, Kusunoki H, Manabe N, et al. Histological evaluation of patients with gastritis at high risk of developing gastric cancer using a conventional index. Pathol Res Pract. 2011;207(6):354–8.

    PubMed  Google Scholar 

  162. Choi YJ, Kim N, Chang H, Lee HS, Park SM, Park JH, et al. Helicobacter pylori-induced epithelial-mesenchymal transition, a potential role of gastric cancer initiation and an emergence of stem cells. Carcinogenesis. 2015;36(5):553–63.

    CAS  PubMed  Google Scholar 

  163. Chuang CH, Yang HB, Sheu SM, Hung KH, Wu JJ, Cheng HC, et al. Helicobacter pylori with stronger intensity of CagA phosphorylation lead to an increased risk of gastric intestinal metaplasia and cancer. BMC Microbiol. 2011;11(1):1–7.

    Google Scholar 

  164. Borges SS, Ramos AFPL, Moraes AVd, Braga CAdSB, Carneiro LC, Barbosa MS. [Article partial retraction] prevalence of helicobacter pylori infection in dyspeptic patients and its association with clinical risk factors for developing gastric adenocarcinoma. Arq Gastroenterol. 2019;56:66–70.

    PubMed  Google Scholar 

  165. Huang H, Tian J, Xu X, Liang Q, Huang X, Lu J, et al. A study on the roles of Helicobacter pylori in bile reflux gastritis and gastric cancer. J BUON. 2018;23(3):659–64.

    PubMed  Google Scholar 

  166. Xie Y, Liu L. Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. Oncol Lett. 2018;16(5):5615–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  167. Pereira J, Santos M, Delabio R, Barbosa M, Smith M, Payão S, et al. Analysis of gene expression of miRNA-106b-5p and TRAIL in the apoptosis pathway in gastric cancer. Genes. 2020;11(4):393.

    CAS  PubMed  PubMed Central  Google Scholar 

  168. Youn Nam S, Park BJ, Nam JH, Ryu KH, Kook MC, Kim J, et al. Association of current Helicobacter pylori infection and metabolic factors with gastric cancer in 35,519 subjects: a cross-sectional study. United European Gastroenterol J. 2019;7(2):287–96.

    PubMed  Google Scholar 

  169. Khatoon J, Prasad K, Prakash Rai R, Ghoshal U, Krishnani N. Association of heterogenicity of Helicobacter pylori cag pathogenicity island with peptic ulcer diseases and gastric cancer. Br J Biomed Sci. 2017;74(3):121–6.

    CAS  PubMed  Google Scholar 

  170. Pandey A, Tripathi SC, Mahata S, Vishnoi K, Shukla S, Misra SP, et al. Carcinogenic Helicobacter pylori in gastric pre-cancer and cancer lesions: association with tobacco-chewing. World J Gastroenterol. 2014;20(22):6860.

    PubMed  PubMed Central  Google Scholar 

  171. Yoon K, Kim N, Park Y, Kim BK, Park JH, Shin CM, et al. Correlation between macrophage migration inhibitory factor and autophagy in Helicobacter pylori-associated gastric carcinogenesis. PLoS One. 2019;14(2):e0211736.

    CAS  PubMed  PubMed Central  Google Scholar 

  172. Wei KL, Chou JL, Chen YC, Low JT, Lin GL, Liu JL, et al. Epigenetic silencing of STAT3-targeted miR-193a, by constitutive activation of JAK/STAT signaling, leads to tumor progression through overexpression of YWHAZ in gastric cancer. Front Oncol. 2021;11:575667.

    CAS  PubMed  PubMed Central  Google Scholar 

  173. Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol. 2018;24(22):2373.

    CAS  PubMed  PubMed Central  Google Scholar 

  174. Ansari S, Yamaoka Y. Survival of Helicobacter pylori in gastric acidic territory. Helicobacter. 2017;22(4):e12386.

    Google Scholar 

  175. Pilotto A, Franceschi M. Helicobacter pylori infection in older people. World J Gastroenterol. 2014;20(21):6364.

    PubMed  PubMed Central  Google Scholar 

  176. Cancer IAfRo. Schistosomes, liver flukes and Helicobacter pylori. IARC working troup on the evaluation of carcinogenic resks to humans. IARC Monogr Eval Carcinog Risks Hum. 1994;61:218–20.

    Google Scholar 

  177. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 1999;13(7):851–6.

    CAS  PubMed  Google Scholar 

  178. Palli D, Masala G, Del Giudice G, Plebani M, Basso D, Berti D, et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer. 2007;120(4):859–67.

    CAS  PubMed  Google Scholar 

  179. Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer. 2006;119(3):702–5.

    CAS  PubMed  Google Scholar 

  180. Kamangar F, Qiao Y, Blaser M, Sun X, Katki H, Fan J, et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer. 2007;96(1):172–6.

    CAS  PubMed  Google Scholar 

  181. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006;98(20):1445–52.

    PubMed  Google Scholar 

  182. Limburg PJ, Qiao Y-L, Mark SD, Wang G-Q, Perez-Perez GI, Blaser MJ, et al. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst. 2001;93(3):226–33.

    CAS  PubMed  Google Scholar 

  183. Stock M, Otto F. Gene deregulation in gastric cancer. Gene. 2005;360(1):1–19.

    CAS  PubMed  Google Scholar 

  184. Spineli LM, Pandis N. Problems and pitfalls in subgroup analysis and meta-regression. Am J Orthod Dentofac Orthop. 2020;158(6):901–4.

    Google Scholar 

  185. Varga MG, Butt J, Blot WJ, Le Marchand L, Haiman CA, Chen Y, et al. Racial Differences in Helicobacter pylori CagA Sero-prevalence in a Consortium of Adult Cohorts in the United StatesRacial Differences in CagA+ H. pylori Prevalence. Cancer Epidemiol Biomarkers Prev. 2020;29(10):2084–92.

    PubMed  PubMed Central  Google Scholar 

  186. Brown H, Cantrell S, Tang H, Epplein M, Garman KS. Racial differences in helicobacter pylori prevalence in the US: a systematic review. Gastro hep advances. 2022;1(5):857–68.

    PubMed  PubMed Central  Google Scholar 

  187. Epplein M, Signorello LB, Zheng W, Peek RM Jr, Michel A, Williams SM, et al. Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomark Prev. 2011;20(5):826–34.

    Google Scholar 

  188. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239.

    CAS  PubMed  PubMed Central  Google Scholar 

  189. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol. 2005;11(38):6009–13.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Author notes

  1. Maryam Shirani and Reza Pakzad contributed equally to this work.

Authors and Affiliations

  1. Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Maryam Shirani

  2. Department of Epidemiology, Faculty of Health, Ilam University Medical Sciences, Ilam, Iran

    Reza Pakzad

  3. Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran

    Reza Pakzad & Saeed Khoshnood

  4. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

    Mohammad Hossein Haddadi, Hossein Kazemian & Saeed Khoshnood

  5. Students’ Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran

    Sousan Akrami

  6. Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Sousan Akrami, Melika Moradi & Morteza Saki

  7. Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

    Arezoo Asadi

  8. Department of Medical Microbiology, Faculty of Medicine, Ilam University of Medical Science, Ilam, Iran

    Vahab Hassan Kaviar

  9. Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Abolfazl Rafati Zomorodi

  10. Department of Midwifery, Faculty of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran

    Mahnaz Shafieian

  11. Department of Medicine, Faculty of Nutrition Science, University of Cheste, Chester, UK

    Ronia Tavasolian

  12. Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran

    Mohsen Heidary

  13. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

    Mohsen Heidary

Authors
  1. Maryam Shirani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Pakzad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Hossein Haddadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sousan Akrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arezoo Asadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hossein Kazemian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melika Moradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vahab Hassan Kaviar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Abolfazl Rafati Zomorodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Saeed Khoshnood
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mahnaz Shafieian
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ronia Tavasolian
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mohsen Heidary
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Morteza Saki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SK, RP, and MHH conceived and designed the study; MHH, SA, AA, HK, MM, and VHK collected and aggregated data; SA, HK, AR, MSha, MShir, and RT analysed the data and wrote the manuscript; MSha, HK, RT, MSak and MH reviewed and revised the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Mohsen Heidary or Morteza Saki.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirani, M., Pakzad, R., Haddadi, M.H. et al. The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis. BMC Infect Dis 23, 543 (2023). https://doi.org/10.1186/s12879-023-08504-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-023-08504-5

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us